On this episode of Stock Movers:
- Sarepta (SRPT) shares soar after the Food and Drug Administration reversed course and recommended that patients who can walk be allowed to take Sarepta Therapeutics Inc.'s gene therapy Elevidys again.
- UPS (UPS) shares fall after the parcel carrier declined to provide full-year revenue or operating profit guidance amid macroeconomic uncertainty. Analysts also flagged soft margins in the US Domestic Package segment.
- Whirlpool (WHR) shares. The company slashed its 2025 profit outlook, saying the boost from making the majority of its appliances in the US has yet to materialize. Chief Financial Officer Jim Peters told Bloomberg that increased promotions by rival Asian appliance makers resulted in Whirlpool seeing a “slight loss in market share” during the period.

On this episode of Stock Movers: - Sarepta (SRPT) shares soar after the Food and Drug Administration reversed course and recommended that patients who can walk be allowed to take Sarepta Therapeutics Inc.'s gene therapy Elevidys again. - UPS (UPS) shares fall after the parcel carrier declined to provide full-year revenue or operating profit guidance amid macroeconomic uncertainty. Analysts also flagged soft margins in the US Domestic Package segment. - Whirlpool (WHR) shares. The company slashed its 2025 profit outlook, saying the boost from making the majority of its appliances in the US has yet to materialize. Chief Financial Officer Jim Peters told Bloomberg that increased promotions by rival Asian appliance makers resulted in Whirlpool seeing a &ldquo;slight loss in market share&rdquo; during the period.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Sarepta Soars, UPS Falls, Whirlpool Drops on Profit Outlook

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ea29d082-da59-4f06-bdb6-b32900fafb6e/transcript

On this episode of Stock Movers:

- Nike (NKE) shares end the day higher after CEO Elliott Hill reported the purchase of about $1 million in shares. Last week, Apple CEO and Nike board member Tim Cook announced he was buying shares of the sportswear company.

- Trump Media and Technology Group (DJT) ends the day up more than 5% after the company said it plans to issue a new cryptocurrency, which will be distributed among its shareholders. Each of Trump Media’s shareholders will receive one token per share, the company said. Trump himself is the company’s largest shareholder with a 41% stake in the business, according to data compiled by Bloomberg.

- Corcept (CORT) shares plunged after US regulators rejected the company’s drug to treat a form of high blood pressure. The Food and Drug Administration “could not arrive at a favorable benefit-risk assessment” for the company’s drug, relacorilant, without more evidence of its effectiveness, the Redwood City, California-based company said in a statement Wednesday.

On this episode of Stock Movers:
- Nike (NKE) shares end the day higher after CEO Elliott Hill reported the purchase of about $1 million in shares. Last week, Apple CEO and Nike board member Tim Cook announced he was buying shares of the sportswear company.
- Trump Media and Technology Group (DJT) ends the day up more than 5% after the company said it plans to issue a new cryptocurrency, which will be distributed among its shareholders. Each of Trump Media&rsquo;s shareholders will receive one token per share, the company said. Trump himself is the company&rsquo;s largest shareholder with a 41% stake in the business, according to data compiled by Bloomberg.
- Corcept (CORT) shares plunged after US regulators rejected the company&rsquo;s drug to treat a form of high blood pressure. The Food and Drug Administration &ldquo;could not arrive at a favorable benefit-risk assessment&rdquo; for the company&rsquo;s drug, relacorilant, without more evidence of its effectiveness, the Redwood City, California-based company said in a statement Wednesday.

Nike, Trump Media End Day Higher; Corcept Plunges

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/70e362b6-f667-467f-ab4a-b3c40162c189/transcript

On this episode of stock movers:
Nike (NKE) shares rose on Wednesday after CEO Elliott Hill reported the purchase of about $1 million in shares.
Corcept (CORT) shares fell after US regulators rejected the company’s drug to treat a form of high blood pressure.
The Food and Drug Administration “could not arrive at a favorable benefit-risk assessment” for the company’s drug, relacorilant, without more evidence of its effectiveness, the Redwood City, California-based company said in a statement Wednesday. 
Trump Media and Technology Group (DJT) shares rose on news the company, which operates President Donald Trump’s Truth Social platform, plans to issue a new cryptocurrency, which will be distributed among its shareholders.

On this episode of stock movers:
<ul>
<li>Nike (NKE) shares rose on Wednesday after CEO&nbsp;Elliott Hill&nbsp;reported the purchase of about $1 million in shares.</li>
<li>Corcept (CORT) shares fell after US regulators rejected the company&rsquo;s drug to treat a form of high blood pressure.</li>
<li>The Food and Drug Administration &ldquo;could not arrive at a favorable benefit-risk assessment&rdquo; for the company&rsquo;s drug, relacorilant, without more evidence of its effectiveness, the Redwood City, California-based company&nbsp;said&nbsp;in a statement Wednesday.&nbsp;</li>
<li>Trump Media and Technology Group (DJT) shares rose on news the company,&nbsp;which operates President&nbsp;Donald Trump&rsquo;s Truth Social platform, plans to issue a new cryptocurrency, which will be distributed among its shareholders.</li>
</ul>

Nike, DJT Rise; Corcept Falls

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/fea92094-bf74-4052-b28a-b3c40132b0ad/transcript

On this episode of Stock Movers:
- Vanda Pharmaceuticals (VNDA) shares soar as much as 24% in premarket trading on Wednesday after the biopharmaceutical company said the US FDA has approved Nereus (tradipitant) for the prevention of vomiting induced by motion.
- Nike (NKE) shares rose 1.6% in postmarket trading after CEO Elliott Hill reported the purchase of about $1 million in shares.
- The S&P 500 Index is poised to end 2025 up more than 17% as the bull market continues for a third year driven by enthusiasm for artificial intelligence. The AI trade broadened out this year, as chip stocks again led the S&P 500 but were joined by the shares of companies tied to building the data centers that will power the technology. Three of the index’s top 10 performers in 2025 were data storage companies, which are among the main beneficiaries of the hundreds of billions of dollars in pledged spending by the giant AI cloud service providers known as hyperscalers. On the flip side, economic uncertainty from President Donald Trump’s sweeping tariffs weighed on the shares of consumer companies, while health-care stocks struggled with uncertainty surrounding the administration’s policies and pressure on drug prices. 

On this episode of Stock Movers: - Vanda Pharmaceuticals (VNDA) shares soar as much as 24% in premarket trading on Wednesday after the biopharmaceutical company said the US FDA has approved Nereus (tradipitant) for the prevention of vomiting induced by motion. - Nike (NKE) shares rose 1.6% in postmarket trading after CEO Elliott Hill reported the purchase of about $1 million in shares. - The&nbsp;S&amp;P 500 Index&nbsp;is poised to end 2025&nbsp;up more than 17%&nbsp;as the bull market continues for a third year driven by enthusiasm for artificial intelligence.&nbsp;The AI trade broadened out this year, as chip stocks again&nbsp;led the S&amp;P 500&nbsp;but were joined by the shares of companies tied to building the data centers that will power the technology. Three of the index&rsquo;s&nbsp;top 10 performers&nbsp;in 2025 were data storage companies, which are among the main beneficiaries of the hundreds of billions of dollars in pledged spending by the giant AI cloud service providers known as hyperscalers.&nbsp;On the flip side, economic uncertainty from President&nbsp;Donald Trump&rsquo;s sweeping tariffs weighed on the shares of consumer companies, while health-care stocks struggled with uncertainty surrounding the administration&rsquo;s policies and pressure on drug prices.&nbsp;

 Vanda Pharmaceuticals Up, Nike Gains, Biggest Winners of 2025

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/03046d85-b293-4560-9b0b-b3c400c6282c/transcript

Sarepta Soars, UPS Falls, Whirlpool Drops on Profit Outlook

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips